Discover how tirzepatide, a next‑generation peptide drug and dual GIP/GLP‑1 receptor agonist, is transforming obesity treatment, improving glycemic control, and reducing cardiometabolic risk through advanced peptide engineering and multi‑receptor targeting.
Discover how next‑generation small‑molecule GLP‑1 receptor agonists are transforming type 2 diabetes and obesity treatment—offering true oral bioavailability, potential for improved tolerability via biased signaling, and scalable manufacturing for global access.
Discover how AI-powered pharmacovigilance is reshaping drug safety monitoring—from automated case intake and NLP for unstructured data to machine learning–driven signal detection and real-time safety intelligence for life science companies and regulators.
Learn what deucravacitinib is, how its selective TYK2 allosteric inhibition works, and how it differs from traditional JAK inhibitors in autoimmune diseases like plaque psoriasis, psoriatic arthritis, SLE, and IBD.
Learn how AI-driven pharmacovigilance uses machine learning, NLP, and advanced analytics to transform drug safety monitoring, enable real-time signal detection, and augment traditional pharmacovigilance workflows.
Discover how tirzepatide, a next‑generation dual GIP/GLP‑1 receptor agonist, delivers powerful HbA1c reduction, significant weight loss, and broader metabolic benefits compared with traditional GLP‑1 drugs like semaglutide and liraglutide.
Explore how machine learning and generative AI are revolutionizing small molecule drug discovery—from data-driven design and ADMET prediction to generative models that “imagine” new drugs and reshape modern pharmacology.
Discover how AI-first signal management is transforming pharmacovigilance from manual case handling to real-time, data-driven drug safety. Learn how AI and machine learning power intelligent case intake, multichannel signal detection, and faster, more precise risk management.
Learn what retatrutide is, how its triple agonist action (GLP‑1, GIP, and glucagon receptors) drives powerful weight loss, boosts energy expenditure, and improves metabolic health, plus key phase 2 clinical trial results.
Discover why KRAS became the iconic “undruggable” oncogene in cancer biology, how covalent KRASG12C inhibitors like sotorasib and adagrasib opened the door, and what’s next for targeting common KRAS mutations such as G12D and G12V in lung, pancreatic, and colorectal cancers.